COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0FX3U
|
|||
Drug Name |
Bevacizumab
|
|||
Synonyms |
Bevacizumab (ophthalmic slow-release tissue tablet); Avastin
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2/3 | [1] | |
Other Indication | Metastatic colorectal cancer | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN vascular endothelial growth factor (VEGF) | Target Info | Inhibitor | [1] |
VEGF is considered as a key factor and a potential therapeutic target in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Higher levels of blood Vascular Endothelial Growth Factor (VEGF) were identified in COVID-19 patients. Bevacizumab, an anti-VEGF monoclonal antibody, is a promising drug for the treatment of ALI/ARDS as well as reduction of mortality in severe and critical COVID-19 patients through suppression of pulmonary edema. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP) | |||
2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.